The stock tanked not because of the short sellers but simply because the drug turned out not to have the risk profile the market was counting on when the stock was at 20. It doesn't do any good to deny this and look to other fantasies to explain the current price.
Feuerstein was right - this drug has problems.
I am not a short. I am very long and have added to my position substantially since the crash, with a current average around 8.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.